Mainz Biomed N.V. [NASDAQ: MYNZ] gained 0.65% on the last trading session, reaching $0.48 price per share at the time.
If compared to the average trading volume of 317.16K shares, MYNZ reached a trading volume of 12221546 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about Mainz Biomed N.V. [MYNZ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYNZ shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYNZ stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Mainz Biomed N.V. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 21, 2023. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 21, 2022, representing the official price target for Mainz Biomed N.V. stock.
The Average True Range (ATR) for Mainz Biomed N.V. is set at 0.10, with the Price to Sales ratio for MYNZ stock in the period of the last 12 months amounting to 11.68. The Price to Book ratio for the last quarter was 3.13, with the Price to Cash per share for the same quarter was set at 0.32.
Trading performance analysis for MYNZ stock
Mainz Biomed N.V. [MYNZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.08. With this latest performance, MYNZ shares dropped by -37.65% in over the last four-week period, additionally sinking by -57.13% over the last 6 months – not to mention a drop of -89.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYNZ stock in for the last two-week period is set at 46.13, with the RSI for the last a single of trading hit 51.40, and the three-weeks RSI is set at 44.06 for Mainz Biomed N.V. [MYNZ]. The present Moving Average for the last 50 days of trading for this stock 0.6283, while it was recorded at 0.4038 for the last single week of trading, and 1.2290 for the last 200 days.
Mainz Biomed N.V. [MYNZ]: A deeper dive into fundamental analysis
Mainz Biomed N.V.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.91 and a Current Ratio set at 0.97.
An analysis of Institutional ownership at Mainz Biomed N.V. [MYNZ]
The top three institutional holders of MYNZ stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in MYNZ stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in MYNZ stock with ownership which is approximately 5.1238%.
